1284. Outcomes by Baseline Pathogens and Susceptibility in the STRIVE Phase 2 Trial of Once-Weekly Rezafungin for Treatment of Candidemia and Invasive Candidiasis Compared with Caspofungin

BACKGROUND: Rezafungin (RZF) is a novel echinocandin in Phase 3 development for treatment of candidemia and invasive candidiasis (IC) and for prevention of invasive fungal disease caused by Candida, Aspergillus, and Pneumocystis in blood and marrow transplant recipients. This analysis of the complet...

Descripción completa

Detalles Bibliográficos
Autores principales: Thompson, George R, Horcajada, Juan P, Locke, Jeffrey B, Viani, Rolando, Pappas, Peter, Ghannoum, Mahmoud, Sandison, Taylor, Soriano, Alex
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Poster Abstracts
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776548/
http://dx.doi.org/10.1093/ofid/ofaa439.1467

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7776548/
http://dx.doi.org/10.1093/ofid/ofaa439.1467

Ejemplares similares